< LEADERBOARD/s/probioticsGut & probiotics

Probiotics

Also sold as: Live microbial cultures · Lactobacillus and Bifidobacterium · Saccharomyces boulardii

Live microorganisms studied for specific indications, formulations and host populations. A strain code, viable dose and matched clinical outcome matter more than a generic species name or a large CFU number.

Anxiety

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

AnxietyLimited · benefit

Anxiety: Small pooled adjunctive effects exist, with marked heterogeneity and no proof that any probiotic product works: anxiety d=-0.10 in one meta-analysis.

REALITY CHECK // More strains or billions do not make a product effective for every condition. Large low-bias acute-diarrhea trials weakened older claims, while a severe-pancreatitis trial found increased mortality. CFU cannot be converted to a clinical dose using powder weight.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

CFU and strain, not mg

No universal mass target exists. Compare a fully identified strain and guaranteed viable dose with its actual trial.

02 // TIMING_&_MATRIX

Protect viability

Follow product storage instructions; avoid hot drinks. Bacterial products and antibacterial doses are usually separated; yeast products differ.

03 // EVALUATION_WINDOW

Indication-specific window

Antibiotic-associated prevention is peri-antibiotic; IBS trials often span 4-12 weeks, respiratory prevention over 3 months.

04 // SAFETY_&_QUALITY_GATE

Host safety comes first

Critical illness, immunosuppression and central catheters require medical decisions. Check CFU through expiry rather than only at manufacture.

UPPER LIMIT // No EFSA/NIH UL is established in this dossier. CFU, strain identity, host immune status and viability at expiry matter; absence of a numerical UL does not establish unrestricted safety.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

The strongest practical signals concern antibiotic-associated diarrhea and adjunctive H. pylori treatment in selected patients. IBS and mood responses are strain-specific and uncertain. Critically ill patients can be harmed.

Mechanism

Transient microbial activity may affect pathogens, barrier signaling, metabolites and gut-brain pathways. Mechanistic plausibility does not establish a benefit for an arbitrary strain or permanent colonization.

Typical studied dose

Trials report strain-specific CFU rather than a universal mg dose. Respiratory prevention studies commonly used 10^9-10^11 CFU/day for over 3 months; IBS studies often lasted 4-12 weeks. These ranges are not transferable to all strains or indications.

Upper limit

No EFSA/NIH UL is established in this dossier. CFU, strain identity, host immune status and viability at expiry matter; absence of a numerical UL does not establish unrestricted safety.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Probiotics

Not enough stack data yet. A combination with Probiotics appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Freeze-dried bacterial capsules: identified strain required Best for: Matching a specific bacterial strain and CFU to an indication.	Unstandardized: active content unknown	no comparable trial range	Survival and effects differ between strains; permanent colonization is not required. Transient gas is possible.	Studied standard [REFERENCE // LABEL_CHECK] Mass calculator disabled: mg cannot infer viable CFU or trial equivalence. PMID 37541528
Enteric / delayed-release bacterial capsules Best for: Assessing formulation claims separately from strain evidence.	Unstandardized: active content unknown	no comparable trial range	Potential survival advantage for acid-sensitive strains; not proven superior for every strain. Usually similar to standard capsules.	Caution [CAUTION // LABEL_CHECK] No mg-to-CFU conversion; an enteric coating alone does not prove superior clinical outcomes.
Saccharomyces boulardii: identify strain such as CNCM I-745 Best for: Checking strain-specific antibiotic-associated diarrhea evidence.	Unstandardized: active content unknown	no comparable trial range	Yeast survives antibacterial drugs but may be inactivated by antifungals. Often tolerated; rare invasive yeast infections are a major host-specific concern.	Good option [GOOD // LABEL_CHECK] Even when labels use mg, viability depends on the product; no generic mg-to-CFU conversion. PMID 34385227
Spore-forming Bacillus preparations Best for: Checking a coded Bacillus strain rather than a broad spore claim.	Unstandardized: active content unknown	no comparable trial range	Heat/acid stability is not equivalent to proven indication-specific efficacy. Some reader-reported symptom flares; causation is uncertain.	Caution [CAUTION // LABEL_CHECK] Evidence breadth differs from conventional strains; no generic dose equivalence.

Common label traps

TRAP_01 // MORE CFU MEANS BETTER
The studied strain, indication and viable amount at expiry matter. A species name without a strain code does not establish trial equivalence.
TRAP_02 // ALWAYS HARMLESS
In PROPATRIA, 296 predicted severe-pancreatitis patients had 24 versus 9 deaths: RR 2.53, 95% CI 1.22-5.25. This cannot be generalized to healthy users, but rules out universal safety.
TRAP_03 // PROBIOTICS CURE ACUTE DIARRHEA
The 2020 Cochrane update found little or no difference in diarrhea lasting >=48 hours in low-bias evidence, unlike older positive findings.
TRAP_04 // FERMENTED FOOD IS THE SAME AS THE TRIAL CAPSULE
Food matrices and strain identity vary. Neither a fermented food nor an expensive capsule guarantees the specific tested strain and dose.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

Antibiotic-associated diarrhea Moderate · benefit
42 RCTs, 11,305 participants: RR 0.63 (0.54-0.73); another review reported NNT 13. Benefit concentrated at moderate/high baseline risk and depends on product.
PMID 34385227 PMID 22570464 PMID 31039287
C. difficile-associated diarrhea prevention Moderate · benefit
The dossier summarizes 31 RCTs, 8,672 participants: RR 0.40 (0.30-0.52), 1.5% vs 4.0%; absolute value depends strongly on baseline risk. This is prevention, not treatment.
PMID 29257353 PMID 40931979
IBS symptoms Limited · benefit
82 RCTs, 10,332 participants in the 2023 update: certainty differs greatly by strain; low/very low for many commonly marketed combinations.
PMID 37541528 PMID 38999862 PMID 35433498
Acute infectious diarrhea Limited · no benefit
Current low-bias Cochrane evidence suggests little/no benefit; selected pediatric strain network analyses remain positive. Neither supports a universal adult claim.
PMID 33295643 PMID 34959871 PMID 31543689
Functional constipation Limited · benefit
14 RCTs, 1,182 adults: transit -12.4 hours (-22.3 to -2.5), +1.3 bowel movements/week (0.7-1.9); B. lactis signal differed from the null L. casei Shirota estimate.
PMID 25099542 PMID 32005532
Adjunctive H. pylori therapy Moderate · benefit
45 RCTs, 6,997 participants in the dossier: ITT eradication RR 1.13 (1.10-1.16), roughly 82% vs 72%; adverse events RR 0.59 (0.48-0.71). Does not replace eradication medicines.
PMID 25892886 PMID 40697099
Respiratory infections Limited · benefit
24 RCTs, 6,950 participants suggest fewer episodes, with low/very-low certainty and diverse age groups.
PMID 36001877 PMID 25927096
SIBO Limited · benefit
Small heterogeneous evidence suggests decontamination and breath-hydrogen effects, but not prevention. Symptom response varies and some users worsen.
PMID 28267052
Severe acute pancreatitis mortality Moderate · makes it worse
Increased mortality in the specific critically ill PROPATRIA population; do not misclassify this as a general longevity outcome.
PMID 18279948 PMID 24684832
Depressive symptoms as adjunct Limited · benefit
Pooled depression d=-0.24; a larger clinical-sample signal is preliminary. No substitution for established mental-health treatment.
PMID 31004628 PMID 41310510

Reader questions

Which strain should I buy?

Match the complete strain code, actual formulation and viable dose to a trial for the specific condition. More strains and CFU are not substitutes for that match.

Can I take it with antibiotics?

Selected products reduced antibiotic-associated diarrhea in higher-risk groups. Discuss the product with the prescriber; bacterial products commonly need timing separation, while S. boulardii differs.

Can it worsen SIBO or cause flares?

Yes, some people report worsening. Strain-specific evidence is limited; stop attributing severe symptoms to adaptation and arrange clinical assessment.

Are probiotics safe every day forever?

Long-term healthy-adult evidence is limited, and host status can change safety. Avoid assuming no UL means no risk.

Stack interactions

Caution Antibacterial drugs [CAUTION // REVIEW]
Timing helps preserve bacterial viability; S. boulardii is a yeast, so the antibacterial distinction matters. These are prevention efficacy sources, not direct timing trials.
PMID 34385227 PMID 22570464
Caution Antifungals [CAUTION // REVIEW]
Can inactivate S. boulardii; this is a viability concern and no direct interaction PMID is extracted.
Caution Immunosuppression / critical illness [CAUTION // REVIEW]
PROPATRIA establishes a severe-pancreatitis harm signal, not a fungemia-specific trial. Invasive-infection risk in immunosuppressed/catheter patients requires separate clinical review.
PMID 18279948
Caution Prebiotic blends / hot liquids [CAUTION // REVIEW]
Fermentable additives may increase gas, and heat may reduce viable cultures. Do not assume a synbiotic or heat-stable marketing claim proves better efficacy.

Red flags: interactions and who should avoid it

Interactions

Bacterial probiotics are commonly separated from antibacterial doses by at least 2 hours to preserve viability. S. boulardii is a yeast and is affected by antifungals rather than antibacterial drugs. Immunosuppression and central venous catheters materially change infection risk.

Avoid or ask a doctor first if

Avoid unsupervised use in critical illness, predicted severe acute pancreatitis, profound immunosuppression/neutropenia, or a central venous catheter. Prematurity and short-bowel syndrome require specialist oversight. Seek care for fever or systemic illness; worsening SIBO/histamine-like symptoms are not proof of a helpful detox response.

Sources (PubMed, 22)

Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis.
PMID 34385227 · 2021 · meta-analysis
42-RCT antibiotic-associated diarrhea review; strain, dose and baseline risk matter.
Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis.
PMID 22570464 · 2012 · meta-analysis
Antibiotic-associated diarrhea review with pooled RR and NNT.
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.
PMID 31039287 · 2019 · meta-analysis
Pediatric antibiotic-associated diarrhea evidence; not interchangeable with an adult product claim.
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
PMID 29257353 · 2017 · meta-analysis
C. difficile-associated diarrhea prevention evidence and baseline-risk dependence.
Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children.
PMID 40931979 · 2025 · meta-analysis
Updated C. difficile-associated prevention review; interpret within the stated population.
Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.
PMID 37541528 · 2023 · meta-analysis
Large IBS review with strain-specific certainty differences.
The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
PMID 38999862 · 2024 · systematic review
IBS network meta-analysis; heterogeneous formulations prevent a generic product claim.
Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
PMID 35433498 · 2022 · systematic review
IBS network meta-analysis, requiring strain-specific interpretation.
Probiotics for treating acute infectious diarrhoea.
PMID 33295643 · 2020 · meta-analysis
Updated acute-diarrhea Cochrane findings weakened older positive conclusions.
Which Probiotic Is the Most Effective for Treating Acute Diarrhea in Children? A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
PMID 34959871 · 2021 · systematic review / meta-analysis
Pediatric network meta-analysis suggesting selected-strain benefit, conflicting with broader low-bias findings.
Efficacy of Lactobacillus rhamnosus GG in treatment of acute pediatric diarrhea: A systematic review with meta-analysis.
PMID 31543689 · 2019 · meta-analysis
LGG pediatric diarrhea evidence; not proof for all strains or adults.
The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials.
PMID 25099542 · 2014 · meta-analysis
Constipation outcomes and strain-specific differences.
Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults.
PMID 32005532 · 2020 · meta-analysis
Additional functional constipation meta-analysis.
Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.
PMID 25892886 · 2015 · meta-analysis
Adjunctive H. pylori eradication and adverse-event outcomes.
Efficacy of probiotics pretreatment in Helicobacter pylori eradication therapy: a systematic review and meta-analysis of clinical outcomes.
PMID 40697099 · 2025 · meta-analysis
Probiotic pretreatment in H. pylori eradication; not probiotic monotherapy.
Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials.
PMID 31004628 · 2019 · meta-analysis
Small pooled depression/anxiety effects and substantial clinical heterogeneity.
The efficacy of probiotics, prebiotics, and synbiotics on anxiety, depression, and sleep: a systematic review and meta-analysis of randomized controlled trials.
PMID 41310510 · 2025 · meta-analysis
Biotics mood/sleep meta-analysis; formulations vary.
Probiotics for preventing acute upper respiratory tract infections.
PMID 36001877 · 2022 · systematic review
Respiratory infection prevention review with low-certainty pooled signals.
Probiotics for preventing acute upper respiratory tract infections.
PMID 25927096 · 2015 · meta-analysis
Earlier respiratory infection prevention evidence.
Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence.
PMID 28267052 · 2017 · meta-analysis
Small SIBO evidence base: decontamination is not prevention.
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
PMID 18279948 · 2008 · randomized controlled trial
PROPATRIA severe acute pancreatitis RCT: increased mortality in this critically ill population.
Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials.
PMID 24684832 · 2014 · meta-analysis
Severe-pancreatitis systematic review; no general safety reassurance.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this